NECLIFE11.90

Nectar Lifesciences Limited

· Pharma & Health
₹ CrorePeersAAREYDRUGSNATCAPSUQMEDICAMEQMEDICOBALPHARMAALPAKREBSBIOHALEOSLABSMcap ₹231 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity0.47-11.89-50.30-50.30
Return on Assets0.23-5.55-47.12-47.12
Return on Capital Employed7.58-8.66-10.25-10.25
Return on Invested Capital2.19-4.12-7.00-6.30
Margins
EBITDA Margin9.08-1.58-1,779.89
Operating Margin5.48-5.31
Incremental Operating Margin1,443.24-1.66
Pretax Margin1.08-9.65-507.94
Net Income Margin0.30-6.79-4,890.30
FCF Margin11.587.51
Additional
Effective Tax Rate72.6629.6234.74156.44
Sustainable Growth Rate0.47-11.89-50.30-50.30
Incremental Operating Margin %1,443.24-1.66-570.87
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.